Analysts’ Opinions Are Mixed on These Healthcare Stocks: Lifecore Biomedical (LFCR), Pyxis Oncology (PYXS) and Bausch + Lomb Corporation (BLCO)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lifecore Biomedical (LFCR), Pyxis Oncology (PYXS) and Bausch + Lomb Corporation (BLCO).
Claim 30% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lifecore Biomedical (LFCR)
In a report released today, Michael Petusky from Barrington maintained a Buy rating on Lifecore Biomedical, with a price target of $5.50. The company’s shares closed last Monday at $4.05, close to its 52-week low of $3.68.
According to TipRanks.com, Petusky is a 2-star analyst with an average return of
Lifecore Biomedical has an analyst consensus of Moderate Buy, with a price target consensus of $6.50, implying a 60.9% upside from current levels. In a report issued on March 13, Craig-Hallum also maintained a Buy rating on the stock.
See the top stocks recommended by analysts >>
Pyxis Oncology (PYXS)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Pyxis Oncology, with a price target of $5.00. The company’s shares closed last Monday at $1.42, close to its 52-week low of $0.99.
According to TipRanks.com, Slutsky is a top 100 analyst with an average return of
Currently, the analyst consensus on Pyxis Oncology is a Strong Buy with an average price target of $5.67, a 278.0% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $5.00 price target.
Bausch + Lomb Corporation (BLCO)
Goldman Sachs analyst David Roman maintained a Hold rating on Bausch + Lomb Corporation yesterday and set a price target of $19.00. The company’s shares closed last Monday at $15.84.
According to TipRanks.com, Roman is a 1-star analyst with an average return of
Bausch + Lomb Corporation has an analyst consensus of Hold, with a price target consensus of $18.82, implying a 17.0% upside from current levels. In a report issued on March 21, TipRanks – xAI also reiterated a Hold rating on the stock with a $16.50 price target.
Read More on LFCR:
Disclaimer & DisclosureReport an Issue
- Lifecore signs CDMO manufacturing services agreement with aesthetics customer
- Lifecore price target lowered to $5 from $8.50 at Stephens
- Lifecore upgraded to Outperform from Market Perform at Barrington
- Lifecore: Near‑Term Revenue Headwinds but Compelling Long‑Term Growth and Valuation Support a Buy Rating
- Morning Movers: National Storage surges following Public Storage buyout
